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The pathogenesis of bovine viral diarrhea virus (BVDV) infections is complex and only partly understood. It remains controversial whether
interferon is produced in cells infected with cytopathic(cp) BVDVs which do not persist in vivo. We show here that a cpBVDV (NADL strain)
does not induce interferon responses in cell culture and blocks induction of interferon-stimulated genes by a super-infecting paramyxovirus.
cpBVDV infection causes a marked loss of interferon regulatory factor 3 (IRF-3), a cellular transcription factor that controls interferon synthesis.
This is attributed to expression of Npro, but not its protease activity. Npro interacts with IRF-3, prior to its activation by virus-induced
phosphorylation, resulting in polyubiquitination and subsequent proteasomal degradation of IRF-3. Thermal inactivation of the E1 ubiquitin-
activating enzyme prevents Npro-induced IRF-3 loss. These data suggest that inhibition of interferon production is a shared feature of both ncp
and cpBVDVs and provide new insights regarding IRF-3 regulation in pestivirus pathogenesis.
Published by Elsevier Inc.Keywords: Interferon regulatory factor-3; Innate immunity; Pestivirus; Bovine viral diarrhea virus; N-terminal protease; Ubiquitination; Retinoic acid inducible
gene I; Toll-like receptor 3; Interferon-stimulated gene; Sendai virusIntroduction
Mammalian cells respond to viral infections by rapid
induction of type I interferons (IFN-α and β) and subsequent
up-regulation of hundreds of IFN-stimulated genes (ISGs),
which establish an antiviral state in host cells and prevent viral
replication (Goutagny et al., 2006; Sen, 2001). Viral nucleic
acids within viral genome or expressed during infection present
major pathogen associated molecular patterns (PAMPs) that are
recognized by membrane-bound Toll-like receptors (TLRs)
and/or the caspase recruitment domain (CARD)-containing,
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adaptor molecules, relaying signals to downstream kinases that
activate a number of transcription factors, among which IFN
regulatory factors (IRFs), nuclear factor kappa B (NF-κB), and
ATF/C-Jun coordinately regulate IFN-β transcription. IRF-3 is
a constitutively expressed, latent transcription factor that plays a
central role in this type I IFN response. It is activated through
the TLR3-Toll-interleukin 1 receptor domain-containing adap-
tor inducing IFN-β (TRIF) pathway, or the RIG-I/melanoma
differentiation-associated gene 5 (MDA5) pathways via the
adaptor, mitochondrial antiviral signaling protein (MAVS, also
known as IPS-1, VISA, or Cardif), following specific phos-
phorylation of a cluster of serine/threonine residues close to its
C-terminus by two non-canonical IκB kinases, Tank-binding
kinase 1 (TBK1) or IKKε. Phosphorylated IRF-3 then dimerizes
and translocates into the nucleus where it associates with the
transcription coactivators, CREB binding protein (CBP)/p300,
to stimulate IFN-β transcription (Akira et al., 2006; Fitzgerald
et al., 2003; Kawai and Akira, 2006, 2007; Kawai et al., 2005;
278 Z. Chen et al. / Virology 366 (2007) 277–292Servant et al., 2002; Seth et al., 2005; Sharma et al., 2003; Xu et
al., 2005; Yamamoto et al., 2002; Yoneyama et al., 2004).
During co-evolution with their hosts, many viruses have
acquired mechanisms that specifically perturb the signaling
mechanisms leading to IRF-3 activation. A prime example is the
hepatitis C virus (HCV), which utilizes its serine protease to
cleave critical adaptor molecules, MAVS and TRIF, thus
disrupting virus-induced IRF-3 activation (Foy et al., 2003; Li
et al., 2005b,c; Lin et al., 2006; Loo et al., 2006; Meylan et al.,
2005).
To maintain cellular homeostasis and prevent tissue damage
due to excessive IFN responses, cells have also evolved
mechanisms to switch off IFN induction (Goutagny et al.,
2006). While these pathways are not yet as well studied, the
abundance of IRF-3 appears to be regulated in part by
proteasome-dependent degradation following virus infections,
although there are both cell type- and virus-specific differences
in how this occurs (Collins et al., 2004; Lin et al., 1998).
Recently, it was reported that dsRNA or viral infection induces
the phosphorylation at Ser339 of IRF-3, in addition to the well-
recognized C-terminal phospho-acceptor sites, resulting in the
recruitment of the peptidyl-prolyl isomerase, Pin1, through a
Ser339–Pro340 motif, and subsequent polyubiquitination and
degradation of IRF-3 via a proteasome-dependent pathway
(Saitoh et al., 2006). The E3 ligases responsible for poly-
ubiquitination of phosphorylated IRF-3 are currently not
known, however, the SKP1-Cullin1-Fbox protein (SCF)
complex, which consists of multi-subunit RING-type E3
ligases, may participate in IRF-3 degradation following Sendai
virus (SeV) infection (Bibeau-Poirier et al., 2006). Importantly,
the NSP1 protein of rotavirus has been recently shown to
interact with IRF-3 and to target it for proteasome-dependent
degradation, suggesting that viruses can potentially exploit
these cellular regulatory pathways to subvert innate host
defenses (Barro and Patton, 2005).
Bovine viral diarrhea virus (BVDV), along with classical
swine fever virus (CSFV) of pigs and border disease virus
(BDV) of sheep, represent a group of important veterinary
viruses that comprise the genus Pestivirus within the family
Flaviviridae. Like the closely related Hepacivirus in this
family, pestiviruses are small enveloped viruses that have a
positive sense, single-stranded RNA genome. The ∼12 kB
pestivirus genome encodes a single polyprotein that is
translated via an internal ribosome entry site-dependent
mechanism, and that is subsequently processed into 11–12
structural and nonstructural (NS) proteins (Rice, 1996).
Unique to the pestiviral polyprotein is the presence of a
small, 20-kDa protein at its N-terminus, the N-terminal
protease (Npro). Npro is a papain-like cysteine protease and
its only well-characterized function is to direct its C-terminal
cis-cleavage from the nascent polyprotein, thereby generating
the mature N-terminus of the nucleocapsid protein (Rumenapf
et al., 1998). Npro has no homologs among members of other
genera in the family Flaviviridae, and has been shown to be
dispensable for the replication of BVDV and CSFV in vitro.
However, for reasons that remain poorly understood, Npro
deletion mutants have impaired viral growth kinetics (Gil etal., 2006; Lai et al., 2000; Ruggli et al., 2003; Tratschin et al.,
1998).
As an economically important cattle pathogen, BVDV
causes significant respiratory and reproductive disease. It exists
as two biotypes: cytopathic (cp) and non-cytopathic (ncp),
depending on the presence of cytopathic effect in cultured cells.
cpBVDVs are derived from ncp viruses by mutations or
genomic recombination and differ from ncpBVDVs in temporal
downregulation of NS2–3 autoprocessing. While efficient
NS2–3 cleavage is observed in cells infected with both
biotypes of BVDVs early after infection, NS2–3 autoproces-
sing is barely detectable at later stages of infection with
ncpBVDVs in contrast to being only moderately decreased
with cpBVDVs. (Lackner et al., 2004). Both cp and ncpBVDVs
can cause acute infections, but only ncpBVDV is able to
establish life-long persistent infection following intra-uterine
infection during the first trimester of pregnancy (Brock, 2003;
Peterhans et al., 2003). While the life-long persistence of
ncpBVDV likely reflects immunotolerance, the mechanisms
underlying the differences in the in vivo phenotypes of
cpBVDV and ncpBVDV remain obscure. Both acute and
persistent BVDV infections were reported to render host
animals more susceptible to a variety of secondary virus
infections (Fulton et al., 2000; Peterhans et al., 2003; Potgieter,
1997), indicating that BVDV infection may disrupt innate or
adaptive host immune responses.
Previous work has shown that BVDV can modulate IFN
induction in host cells. While it remains controversial regarding
whether cpBVDVs trigger IFN production, it is well established
that infection with ncpBVDVs does not induce type I IFNs in
vitro (Brackenbury et al., 2003; Charleston et al., 2001; Gil et
al., 2006; Peterhans et al., 2003; Schweizer et al., 2006).
Furthermore, ncpBVDV infection has been shown to block the
induction of IFN synthesis by dsRNA or a super-infecting virus,
Semliki Forest virus (Baigent et al., 2002; Schweizer and
Peterhans, 2001). These observations suggest that ncpBVDVs
may encode one or more proteins that disrupt IFN signaling
pathways. Unlike the closely related hepacivirus and hepaci-
virus-like GBV-B, the NS3/4A protease of BVDV does not
inhibit viral activation of the IFN-β promoter (Chen et al., 2007;
Horscroft et al., 2005). Instead, accumulating evidence has
suggested a role for Npro as an IFN antagonist (Gil et al., 2006;
Horscroft et al., 2005; La Rocca et al., 2005; Ruggli et al.,
2005).Using a reverse genetics approach, Gil et al. (Gil et al.,
2006) recently reported that mutations close to the N-terminus
of Npro modulate the ability of BVDV to trigger IFN induction,
suggesting that the N-terminal domain of BVDV Npro may be
important for IFN antagonism (Gil et al., 2006). Similarly, an
Npro-deletion mutant CSFV lost the ability to block poly(I-C)-
induced IFN production and induced IFN synthesis sponta-
neously in cell culture (Ruggli et al., 2003). Two recent reports
suggested that the Npro of CSFV down-regulates IRF-3 at the
promoter level (La Rocca et al., 2005) or posttranscriptionally
by inducing its proteasomal degradation (Bauhofer et al., 2007).
Here, we show that infection of cells with a cpBVDV strain,
NADL, not only fails to trigger an IFN response, but also
actively blocks the expression of ISGs normally triggered by
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NADL, when expressed alone or in the context of BVDV
infection, specifically targets IRF-3 for polyubiquitination and
subsequent proteasome-dependent degradation through a PIN1-
independent mechanism, significantly reducing the available
IRF-3 abundance and resulting in disruption of cellular IFN
responses.
Results
Virus-induced IFN response is abrogated in cpBVDV infected
cells
Although infection with ncpBVDVs blocks IFN induction in
cultured cells, previous studies have provided contradictory
results concerning the ability of cpBVDV infection to trigger
IFN synthesis. In an effort to clarify these earlier results, we
determined the effect of infection with a cpBVDV strain,
NADL, on induction of MxA and ISG15, two well-character-
ized ISGs, in bovine kidney MDBK cells. Initial experiments
assessed whether MDBK cells respond to the presence of
extracellular poly(I-C) or infection with Sendai virus (SeV), a
paramyxovirus that is unrelated to BVDV, well-characterized
inducers of type I IFN synthesis through the TLR3 and RIG-I
pathways, respectively (Fitzgerald et al., 2003; Yoneyama et al.,
2004). MDBK cells do not appear to possess an active TLR3
pathway, as even large amounts of extracellular poly (I-C)
induced neither ISG15 nor MxA synthesis (Fig. 1A). In
contrast, infection of MDBK cells with SeV led to the
expression of readily detectable bovine ISG15 and MxA
proteins, indicating the presence of a functional RIG-I pathway
in these cells (Fig. 1A). Remarkably, this response was lost in
MDBK cells infected with BVDV NADL (Fig. 1B, compare
lanes 2 and 4), which also did not induce the expression ofFig. 1. Virus-induced IFN response is abrogated in cpBVDV infected cells.
(A) MDBK cells were mock-treated (lane 1), or incubated with 50 μg/ml poly
(I-C) in culture medium (lane 2) or infected with 100 HAU/ml SeV for 16 h
(lane 3) prior to cell lysis and immunoblot analysis of bovine (bv) ISG15, MxA,
IRF-3 and actin. A nonspecific band (*) detected by the anti-MxA antiserum
indicated equal loading. (B) MDBK cells were mock-infected (lanes 1 and 2) or
infected with BVDV NADL (MOI=10, lanes 3 and 4) for 8 h and subsequently
mock-challenged (lanes 1 and 3) or challenged with SeV (lanes 2 and 4) for 16 h
followed by cell lysis and immunoblot analysis of bv ISG15, MxA, IRF-3, SeV,
BVDV NS3, and actin.bovine ISG15 and MxA (Fig. 1B, compare lanes 3 vs. 1). The
lack of ISG induction in BVDV-infected cells was not due to
interference with replication of the super-infecting SeV, as
similar levels of SeV proteins were expressed, regardless of
BVDV infection status (SeV panel, compare lanes 4 vs. 2).
Thus, like ncpBVDV (Baigent et al., 2002; Schweizer and
Peterhans, 2001), infection of MDBK cells with the cytopathic
NADL strain of BVDV disrupts virus-induction of the IFN
response.
Importantly, expression of the bovine IRF-3 protein was
reduced to nearly undetectable levels in MDBK cells infected
with BVDVNADL (Fig. 1B, compare lanes 3 vs. 1). In contrast,
IRF-3 protein level did not change in cells infected with SeV
(Fig. 1B, compare lanes 2 vs. 1). We conclude from these data
that infection of cells with a cpBVDVablates the virus activation
of IFN responses, at least in part, by severely down-regulating
the abundance of IRF-3.
Npro inhibits activation of IRF-3-dependent promoters by
acting downstream of the IRF-3 kinases
The fact that infection with either ncp or cpBVDV inhibits
virus-induced IFN response suggests that BVDVexpresses one
or more proteins that disrupt IFN-signaling pathways, most
likely by down-regulating the abundance of IRF-3. Previous
studies have suggested a role for BVDV Npro as an IFN
antagonist, although the underlying mechanism(s) have not
been well characterized (Gil et al., 2006; Horscroft et al., 2005).
Consistent with this, we found that ectopic expression of the
NADL Npro protein in HEK293 cells strongly inhibited SeV
activation of the IFN-β promoter in a dose-dependent fashion
(Fig. 2A). Similar results were obtained when the ISG56
promoter was used as a reporter (data not shown). As
transcriptional induction of the IFN-β promoter involves
coordinate activation of both the IRF-3 and NF-κB transcription
factors (Sen, 2001), we investigated the effect of Npro
expression on SeV-activation of the IRF-3-responsive PRDIII-
I and NF-κB-dependent PRDII elements of the human IFN-β
promoter. As shown in Fig. 2B, ectopic expression of Npro
effectively blocked SeV-induced activation of the PRDIII-I
promoter, but had no demonstrable effect on activation of the
PRDII promoter. Similar results were obtained when ectopic
expression of the constitutively active RIG-I CARD was used in
place of SeV infection to trigger the signaling (data not shown).
These results contrast sharply with the impact of the HCV and
GBV-B NS3/4A proteases on these pathways, as they strongly
inhibit the activation of both promoters (Fig. 2B) (Chen et al.,
2007; Foy et al., 2005), and suggest that Npro specifically
inhibits expression of IRF-3-dependent genes downstream of
RIG-I.
As RIG-I signaling bifurcates at the adaptor protein MAVS,
either to the noncanonical IκB kinases, TBK1 and IKKε leading
to the phosphorylation and activation of IRF-3, or to the
classical IKK complex that results in the activation of NF-κB
(Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2006; Xu et
al., 2005), we postulated that Npro acts at or below the level of
TBK1 and IKKε as it only affects the IRF-3 response.
Fig. 2. BVDV NADL Npro inhibits the activation of IRF-3-dependent
promoters initiated by either RIG-I or TLR3 pathways. (A) In left panel,
HEK293 cells were cotransfected with IFN-β-Luc and pCMVβgal plasmids,
and plasmids encoding HCV NS3/4A (positive control), or BVDV NS3/4A, or
BVDV Npro, or a control vector. Twenty-four hours later, cells were either
mock-infected (empty bars) or infected with SeVat 100 HAU/ml for 16 h (solid
bars) prior to lysis for both luciferase and β-galactosidase assays. Bars show
relative luciferase activity normalized to β-galactosidase activity, i.e., IFN-β
promoter activity. Right panel shows IFN-β promoter activity in 293T cells
transfected with increasing amounts (0, 0.1 and 0.3 μg) of Npro-expressing
plasmid supplemented with a control vector to keep the total amount of DNA
transfected constant, then mock-infected or infected with SeV. (B) Activation of
IRF-3-dependent PRDIII-I promoter (4-time repeat of the PRDIII-I element,
left) or NF-κB-dependent PRDII promoter (right) in TH1 cells expressing HCV
NS3/4A (positive control), BVDV Npro, or a control vector, and mock-infected
(empty bars) or infected with SeV (solid bars). (C) Activation of IFN-β
promoter by ectopic expression of IKKε or MAVS in HEK293 cells in the
presence of ectopic co-expression of Npro (solid bars) or a control vector (empty
bars). (D) IFN-β promoter activity in 293-TLR3 cells transfected with a control
vector or Npro, and mock-treated (empty bars) or incubated with 50 μg/ml poly
(I-C) in culture medium for 8 h (Solid bars).
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activation of the IFN-β promoter by ectopically expressed
MAVS (Fig. 2C), or by ectopic expression of either of the IRF-3
kinases, IKKε (Fig. 2C) or TBK1 (data not shown). Ectopically
expressed Npro also inhibited extracellular poly (I-C)-induced
IFN-β promoter activity in HEK293 cells stably expressing
TLR3 (293-TLR3 cells, Fig. 2D), consistent with the require-
ment for TBK1 and IKKε in activation of IRF-3 through the
TLR3 pathway (Fitzgerald et al., 2003; Sharma et al., 2003).
Similar results were obtained when TRIF was expressed
ectopically in lieu of extracellular poly (I-C) as a means to
activate TLR3 signaling (data not shown). Collectively, these
data indicate that the BVDV Npro specifically disrupts IRF-3-
dependent innate defenses triggered by both RIG-I and TLR3
by acting downstream of the IRF-3 kinases. This is consistent
with the loss of IRF-3 expression observed in BVDV NADL-
infected MDBK cells (Fig. 1B).
The full-length Npro protein, but not Npro protease activity, is
required for inhibition of IFN responses
We next sought to determine whether the protease activity of
Npro is required for its inhibition of the IFN response, a
property that is shared by HCV and GBV-B NS3/4A serine
proteases (Chen et al., 2007; Foy et al., 2003). Npro is a papain-
like cysteine protease that contains a triad active site, Glu22–
His49–Cys69 (Rumenapf et al., 1998). Mutations at any of
these 3 residues abolish the protease activity of Npro. To
determine whether this protease activity is required for Npro
disruption of the viral activation of the IFN-β promoter, we
constructed vectors expressing Npro mutants with active site
substitutions: E22V, H49L, or C69A. We confirmed that these
mutants were indeed deficient in protease activity by construct-
ing several Np-CAT fusion constructs in which a c-myc tag and
a CAT reporter gene were fused to the N- and C-termini of Npro,
respectively, with the Npro cis-cleavage site reconstructed
between Npro and CAT (Fig. 3A). The wild-type (WT) Np-CAT
fusion construct, when ectopically expressed in HEK293 cells,
auto-processed to mature Npro (Fig. 3B, lanes 2 and 7) and CAT
(not shown), respectively. However, mutant Np-CAT constructs
carrying individual active site substitutions (E22V, H49L, or
C69A) were expressed exclusively as unprocessed Np-CAT
fusion proteins (Fig. 3B, lanes 3–5), confirming that each of
these 3 residues is essential for the activity of the Npro protease.
When ectopically expressed in HEK293 cells, the E22V and
H49L mutant Npro did not inhibit viral induction of IFN-β
promoter, while the C69A mutant remained capable of
disrupting the IFN response (Fig. 3C). These data confirm
previous studies indicating that Npro protease activity is not
required for disruption of the IFN response, and are concordant
with a recent report in which mutated cpBVDVs carrying
similar E22L or H49V mutations in Npro induced IFN in cell
culture, while a C69A mutant did not (Gil et al., 2006). We
speculated that the E22Vand H49L substitutions may ablate the
effect of Npro on IFN induction by altering the folding/
conformation of Npro independent of their disruption of the
protease active site. To confirm this, we characterized the ability
Fig. 3. The full-length Npro protein, but not its protease activity, is required for
inhibition of IFN response. (A) Schematic representation of the Npro-CAT
(Np-CAT) fusion constructs with or without various point mutations in Npro.
Letters in bold face at below represent the consensus sequence of Npro protease
recognition site. (B) HEK293 cells were transiently transfected with an empty
vector or individual Np-CAT constructs encoding the WT sequence or carrying
various point mutations, and subsequently lysed for immunoblot analysis using
an anti-myc-tag antibody. The positions of mature Npro and unprocessed
Np-CAT were marked by arrow head and circle, respectively. * denotes
nonspecific bands. Note that the L8P mutant Npro (lane 8) migrated slightly
slower than WT Npro (lanes 2 and 7). (C) IFN-β promoter activity in HEK293
cells transfected with an empty vector, or WT Npro, or the indicated Npro point
mutants, and then mock-infected or infected with SeV. (D) Left panel, schematic
representation of full-length (FL) Npro and various Npro truncation mutants.
Numbers indicate aa positions fromN-terminus except that C99 represents the C-
terminal 99 aa. Right panel shows SDS-PAGE of in vitro translated products of
the individual Npro constructs shown in left panel. Full-length (FL) Npro and the
individual Npro deletion mutants were expressed in vitro and labeled with [35S]-
Met using the TNT T7 Coupled Transcription/Translation System (Promega)
according to the manufacturer's instructions. (E) IFN-β promoter activity in
HEK293 cells transfected with an empty vector, or FL Npro, or the indicated
Npro truncation mutants, and mock-infected or infected with SeV.
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retains catalytic activity but is likely to have altered folding
within the N-terminal domain due to the nonconservative nature
of the amino acid substitution. cpBVDV carrying an L8P Npro
mutant was shown to induce IFN in cell culture (Gil et al.,
2006). We confirmed that L8P Npro retained protease activity
(Fig. 3B, lane 8), and demonstrated that it no longer inhibited
virus activation of the IFN-β promoter (Fig. 3C). Importantly,
L8P Npro migrated more slowly than WT Npro in denaturing
SDS-PAGE (Figs. 3B, 4B and 7C), most likely due to altered
conformation. Taken together, these results confirm recent
reports from other laboratories that BVDV disruption of the IFN
response does not require Npro protease activity (Gil et al.,
2006; Hilton et al., 2006). Additional analyses with Npro
deletion mutants demonstrated that constructs expressing only
residues 1–69 (Npro-N69) or 99–168 (Npro-C99) of Npro
lacked the ability to disrupt IFN responses (Figs. 3D and E).
This was also the case with a mutant lacking only 24 aa from the
C-terminus of Npro (Npro-N144). These results are consistent
with data published recently by Hilton et al. (Hilton et al., 2006)
which demonstrated that removal of 30 residues from the
N-terminus or 88 residues from the C-terminus abolished the
IFN-inhibitory function of a ncp pe515 Npro, and indicate that
the nearly full-length sequence of Npro is required for its
function as an IFN antagonist.
Npro down-regulates IRF-3 protein abundance but does not
affect virus-induced IRF-3 activation
To better characterize the role of Npro in antagonizing the
IFN response and potentially down-regulating IRF-3 abun-
dance, we developed HeLa cell lines that conditionally express
NADL Npro, and as controls, the L8P mutant Npro, using the
Tet-Off gene expression system. We selected two WT Npro-
inducible cell lines, Npro-25 and Npro-29, and three L8P
mutant Npro-inducible cell lines, L8P-1, -22 and -38, for further
analysis. As seen in Fig. 4A, the expression of Npro (WT or
L8P) was tightly regulated by tetracycline, occurring when
these cells were cultured in its absence (data from Npro-25, -29
cells and L8P-1 cells were shown). We also established stably
transduced MDBK cells with constitutive expression of WT
(BK-Npro), L8P Npro (BK-L8P), or the control vector (BK-
Pur), using retroviral-mediated gene transfer (Fig. 4B).
Consistent with the reporter data, we found that SeV-induced
ISG56 expression was significantly reduced in both Npro-25
and Npro-29 cells when WT Npro expression was de-repressed
(-tet) (Fig. 4A, ISG56 panel, compare lanes 4 vs. 2 and 8 vs. 6).
In contrast, induction of the L8P mutant Npro had little effect on
SeV-activated ISG56 expression in L8P-1 (Fig. 4A, ISG56
panel, compare lanes 12 vs. 10), L8P-22, and L8P-38 cells (data
not shown). Similar inhibition of SeV-induced bovine ISG15
expression was observed in BK-Npro cells that constitutively
express WT Npro, but not in the related BK-L8P or BK-Pur
cells (Fig. 4B). Using real-time PCR analysis, we also
confirmed that Npro expression significantly reduced SeV-
induced IFN-β mRNA transcripts in Npro-29 cells (Fig. 4C).
We also observed that the induction of ISG56 expression in
Fig. 4. Ectopic expression Npro reduces IRF-3 protein abundance and inhibits the induction of IRF-3 target genes. (A) HeLa cell lines with tet-regulated expression of
WT Npro (Npro-25 and Npro-29 cells, left panel) or L8P mutant Npro (L8P-1, right panel) were cultured to repress (+tet) or induce (−tet) Npro expression for 3 days,
followed by mock infection or infection with 100 HAU/ml SeV for 16 h prior to cell lysis and immunoblot analysis of whole cell extracts for IRF-3, ISG56, SeV, Npro
(using an anti-myc tag antibody) and actin. (B) Populations ofMDBK cells with stable expression of a control vector (Pur, lanes 1 and 2),WTNpro (Npro, lanes 5 and 6)
or L8Pmutant Npro (L8P, lanes 3 and 4) were mock-infected (lanes 1, 3, and 5) or infected with SeV (lanes 2, 4, and 6) for 16 h before cell lysis and immunoblot analysis
of bv IRF-3 and ISG15, SeV and actin. WT and L8P mutant Npros were detected with an anti-myc tag antibody and their positions were marked by line and arrow,
respectively. (C) Real-time RT-PCR analysis of IFN-β mRNA transcripts in HeLa Npro-29 cells repressed or induced for Npro expression, and mock-infected or
infected with SeV. mRNA abundance was normalized to cellular 18S ribosomal RNA. (D) Npro-29 cells repressed (+tet) or induced (−tet) for Npro expression were
mock-treated or incubated with 50 μg/ml poly (I-C) in culture medium for 15 h before cell lysis for immunoblot analysis of ISG56, IRF-3, Npro and actin.
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Npro expression (Fig. 4D, compare lanes 4 vs. 2), confirming
that Npro also inhibits the expression of endogenous IRF-3
target genes following TLR3 engagement.
Importantly, the induction of Npro expression led to a
significant reduction in IRF-3 protein abundance in both Npro-
25 and 29 cells (Fig. 4A, IRF-3 panel, compare lanes 3 vs. 1
and 7 vs. 5, and Fig. 4D, compare lanes 3 vs. 1), while Npro
expression was associated with reduced IRF-3 abundance in the
stably transduced BK-Npro cells (Fig. 4B, compare lanes 5 and 6
vs. 1 and 2). In contrast, this was not observed in L8P mutant-
expressing cells, L8P-1 (Fig. 4A, compares lanes 11 vs. 9), L8P-
22 and L8P-38 cells (data not shown), or BK-L8P cells (Fig. 4B,
compare lanes 3 and 4 vs. 1 and 2). The abundance of RIG-I,
TBK1, or IKKεwas not affected by Npro expression in Npro-29
cells (data not shown). Collectively, these results indicate that
the expression of Npro down-regulates the abundance of IRF-3,
and that this is responsible for the disruption of virus-induced
IFN responses in cells infected with cpBVDV.
Importantly, despite the reduction in protein expression, the
residual IRF-3 was still phosphorylated following SeV infectionin NADL Npro-expressing cells (Fig. 4A, compare lanes 3 vs. 4,
and 7 vs. 8). To confirm that NADL Npro expression does not
affect the activation of IRF-3, we studied the tet-inducible cell
lines for evidence of virus-induced IRF-3 nuclear translocation
and association of IRF-3 with CBP, both well characterized
indicators of IRF-3 activation (Lin et al., 1998). We found that
IRF-3 remained capable of translocating to the nucleus
following SeV challenge in cells expressing Npro (Fig. 5A).
The percentage of SeV-infected cells with nuclear IRF-3,
however, was less in cells induced for Npro expression (−tet),
probably as a result of decreased IRF-3 abundance which
rendered the detection of nuclear IRF-3 more difficult (data not
shown). Co-immunoprecipitation experiments demonstrated
that the residual IRF-3 was also capable of associating with
CBP upon SeV challenge, regardless of Npro expression status,
in both Npro-25 and -29 cells (data not shown). Furthermore,
ectopic expression of IRF-3, but not IKKε, was able to
overcome the Npro disruption of SeV activation of the IFN-β
promoter (Fig. 5B), suggesting that IRF-3 can be activated upon
virus infection in the presence of NADL Npro. These results
suggest that NADL Npro disrupts IFN responses by reducing
Fig. 5. NADLNpro does not affect virus-induced IRF-3 activation. (A) Immunofluorescence staining of IRF-3 inNpro-25 cells, repressed (+tet, upper panels) or induced
(−tet, middle and lower panels) for Npro expression, and mock infected (left panels) or infected with SeV (right panels) for 16 h. Exposure time was kept constant when
pictures were taken for upper and middle panels. The lower panels represent prolonged exposure of the middle panels to better demonstrate the IRF-3 localization. (B)
Activation of IFN-β promoter by ectopic expression of IRF-3, IKKε, or a control vector in HEK293 cells cotransfected with an empty vector or Npro-expressing
plasmid. 20 h later, transfected cells were mock-infected or infected with SeV for 16 h before cell lysis for luciferase and β-galactosidase assays.
283Z. Chen et al. / Virology 366 (2007) 277–292the available levels of IRF-3, and that NADL Npro does not
seem to alter the activation pathways that control IRF-3
phosphorylation, nuclear translocation or the induction of
IFN-β transcription. These results contrast with those reported
by Hilton et al. in studies using HEp2 cells stably expressing
ncp-pe515 Npro, in which Npro also inhibited IRF-3 binding to
DNA (Hilton et al., 2006). Further investigation will be needed
to determine whether this discrepancy is related to cell type
differences and/or differences in the Npro amino acid sequences
(about 8%) of the viral strains used in the two studies.
Npro down-regulates IRF-3 at a post-transcriptional level
Next, we asked whether IRF-3 transcription is down-
regulated by NADL Npro. This seemed likely, as the CSFV
Npro has been reported to down-regulate IRF-3 mRNA
transcription (La Rocca et al., 2005). IRF-3 is constitutively
expressed, and its activity and steady-state abundance are known
to be regulated mainly by post-transcriptional modifications,
such as phosphorylation and proteasome-mediated degradation,
usually following viral infections (Lin et al., 1998; Lowther et
al., 1999). Using a promoter based reporter assay, we found that
the human IRF-3 promoter [in pIRF3(-779)-Luc] was constitu-
tively active, similar to the strong SV40 promoter (in pGL3-
control), and that its activity was not affected by co-expression
of the WT or L8P mutant Npro (Fig. 6A). Real-time PCR
analysis confirmed that IRF-3 mRNA levels did not change
following the induction of Npro expression and/or SeV
infection in Npro-29 cells (Fig. 6B). Furthermore, northern
blot analyses showed that the abundance of IRF-3 mRNA
was not reduced in cells expressing the WT or L8P mutant
Npro (Fig. 6C), although WT Npro expression significantly
reduced virus-induced ISG56 mRNA levels (Fig. 6C). Finally,
despite the ablation of IRF-3 protein expression in cpBVDV
NADL-infected MDBK cells (Fig. 1B), there was little changein the bovine IRF-3 mRNA abundance (Fig. 6D). As expected,
the cpBVDV-infected cells showed a significant reduction in
the abundance of SeV-induced bovine ISG15 mRNA (Fig.
6D). Taken together, these data indicate that, in contrast to
the results reported by La Rocca et al. previously (La Rocca
et al., 2005), the Npro of cpBVDV does not inhibit IRF-3
mRNA transcription but rather down-regulates IRF-3 post-
transcriptionally.
Npro induces polyubiquitination of IRF-3 and promotes
proteasome-mediated degradation of IRF-3
The ubiquitin-proteasome degradation pathway represents a
major, non-lysosomal protein degradation system that regulates
the expression of many proteins involved in diverse cellular
processes (Liu et al., 2005). It is known to play a role in
controlling IRF-3 abundance, and SeV infection is known to
induce the proteasomal degradation of IRF-3 in some cell types
(Lin et al., 1998). To determine whether Npro induces the
proteasome-dependent degradation of IRF-3, we treated
NADL-infected MDBK cells with increasing concentrations
of epoxomicin, a potent mammalian 26S proteasome inhibitor
(Meng et al., 1999), and determined bovine IRF-3 protein
levels by immunoblot analysis. As shown in Fig. 7A, treatment
with as little as 50 nM epoxomicin dramatically restored the
abundance of IRF-3 in NADL-infected cells, but had little
effect on IRF-3 abundance in non-infected cells. This was
accompanied by an accumulation of poly-ubiquitinated cellular
proteins, demonstrating the effectiveness of epoxomicin in
inhibiting the proteasome. At 50 nM concentration, epoxomicin
had little effect on BVDV replication, as expression of BVDV
NS3 was minimally affected (Fig. 7A, compare lanes 5 vs. 6).
At higher concentrations (100 and 500 nM), epoxomicin
decreased the BVDVNS3 protein levels, presumably as a result
of cell toxicity (Fig. 7A, lanes 7 and 8). Treatment with 40 nM
Fig. 6. Npro down-regulates IRF-3 expression at post-transcriptional level. (A)
HEK293 cells were co-transfected with pCMVβgal (internal control) and pGL3-
control (driven by SV40 promoter, left) or pIRF3(-779)-Luc (right), and
plasmids encoding WT Npro (solid bars), or L8P mutant Npro (hatched bars), or
a control vector (empty bars). 24 h later, cells were lysed for both luciferase and
β-galactosidase assays. (B) Real-time RT-PCR analysis of IRF-3 mRNA
transcript in HeLa Npro-29 cells repressed or induced for Npro expression, and
mock-infected or infected with SeV. mRNA abundance was normalized to
cellular 18S ribosomal RNA. (C) L8P-1 and Npro-25 cells were repressed (+tet)
or induced (−tet) for Npro (L8P mutant or WT, respectively) expression for
3 days, followed by mock-infection (lanes 1, 3, 5 and 7) or challenge (lanes 2, 4,
6, and 8) with SeV for 8 h prior to total RNA extraction and northern blot
analysis of ISG56, IRF-3 and Npro mRNAs. An ethidium bromide (EtBr)
staining image of the RNA gel was included to show equal loading of the RNA
samples. (D) MDBK cells were mock-infected (lanes 1 and 2) or infected with
BVDVNADL (MOI=10, lanes 3 and 4) for 8 h and subsequently mock-infected
(lanes 1 and 3) or challenged with SeV (lanes 2 and 4) for 16 h. Total cellular
RNA was isolated, fractionated on denaturing gel, followed by northern blot
analysis of bv ISG15 and IRF-3. An ethidium bromide (EtBr) staining image of
the RNA gel was included to show equal loading of the RNA samples.
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stably expressing NADL Npro (Fig. 7B, IRF-3 panel, compare
lanes 2 and 3 vs. 1). MG115, an alternative 26S proteasome
inhibitor, also significantly elevated IRF-3 protein levels in
Npro-expressing MDBK cells, but was more toxic than
epoxomicin (data not shown). These results are consistent with
ncp pe515 Npro-mediated proteasome-dependent degradation
of IRF-3, as recently reported by Hilton et al. (Hilton et al.,
2006).
We next sought to determine whether Npro-mediated down-
regulation of IRF-3 abundance is dependent on the polyubi-
quitination of IRF-3, a step required for many (but not all)
proteins to be degraded via the proteasome (Liu et al., 2005). Toassess this possibility, we utilized murine fibroblast ts20 cells
which express a temperature-sensitive E1 ubiquitin-activating
enzyme (Chowdary et al., 1994). When ts20 cells are shifted
from a permissive temperature (35 °C) to a restrictive tempe-
rature (39 °C), the E1 ubiquitin-activating protein is inactivated
and as a result, cells fail to degrade proteins that are degraded
through the ubiquitin-proteasome pathway (Chowdary et al.,
1994). We first made stable populations of ts20 cells that
express WT Npro, and as controls, the L8P Npro mutant and
related vector (Pur), respectively, using retroviral gene transfer.
We then compared the IRF-3 protein abundance in these cells
when they were cultured at either 35 °C or 39 °C. As shown in
Fig. 7C, when cells were cultured at 35 °C, detectable IRF-3
protein expression was nearly completely ablated in Npro-
expressing ts20 cells, compared with cells expressing the related
L8P mutant or empty vector (compare lanes 3 and 4 vs. 1 and 2).
However, there was no difference in the abundance of IRF-3
protein in these cells when they were cultured at the restrictive
temperature, 39 °C, at which the E1 ubiquitin-activating
enzyme expressed by ts20 cells is inactive (compare lanes 7
and 8 vs. 5 and 6). These data unambiguously demonstrate that
ubiquitination is an indispensable step in Npro-induced IRF-3
degradation.
As these experiments were in progress, Hilton et al. (Hilton
et al., 2006) reported that Npro from a ncpBVDV (pe515 strain)
targets IRF-3 for polyubiquitination and proteasomal degrada-
tion in HEp2 cells (Hilton et al., 2006). They showed that co-
treatment of cells with ZAVD-fmk, a general caspase inhibitor,
improved the viability of cells treated with a proteasome
inhibitor, probably by blocking the apoptosis induced by a
variety of chemical inhibitors of the proteasome (Nencioni et
al., 2005). We used this approach to demonstrate that cpNADL
Npro induces IRF-3 polyubiquitination in our tet-regulated
Npro HeLa cells (Fig. 7D). Combined treatment of Npro-
expressing (−tet) cells with epoxomicin and ZVAD resulted in a
heterogeneous high molecular mass protein complex that could
be immunoprecipitated by antibody to IRF-3 and reacted with
antibody to ubiquitin (Fig. 7D). This was evident in Npro-
expressing cells treated only with epoxomicin, but was more
readily detected in cells treated with both epoxomicin and
ZVAD (Fig. 7D, compare lanes 11 vs. 12). No high mass
complex was evident in the absence of Npro expression even in
cells treated with both epoxomicin and ZVAD. These
observations were also confirmed in MDBK cells. While WT
Npro induced the polyubiquitination of IRF-3, the L8P mutant
Npro failed to do so under similar conditions (Fig. 7E),
consistent with its inability to down-regulate IRF-3 (Figs. 4A,
B, and 7C). Thus, in agreement with recent observations
concerning the Npro from a ncpBVDV strain (Hilton et al.,
2006), cp NADL Npro also induces polyubiquitination and
proteasomal degradation of IRF-3. Importantly, these results
also demonstrate that the inability of a mutant Npro (L8P) to
induce IRF-3 degradation parallels its inability to target IRF-3
for polyubiquitination (Fig. 7E). This is consistent with the data
shown in Fig. 7C, which indicate that Npro-mediated IRF-3
proteasomal degradation requires the polyubiquitination of
IRF-3.
Fig. 7. Npro induces IRF-3 polyubiquitination and its subsequent degradation through a proteasome-dependent pathway. (A) MDBK cells were mock-infected (lanes 1
through 4) or infected with BVDV NADL at an MOI=10 (lanes 5 through 8). 3 h later, cells were mock-treated or incubated with indicated concentrations of
epoxomicin for further 20 h before cell lysis and immunoblot analysis of bv IRF-3, BVDV NS3, and ubiquitin. (B) MDBK cells with stable expression of WT NADL
Npro (lanes 1 through 3) or L8P mutant Npro (lanes 4 through 6) were cultured in the presence (lanes 2, 3, 5 and 6) or absence (lanes 1 and 4) of 40 nM epoxomicin for
20 h before cell lysis and immunoblot analysis of bv IRF-3, Npro (using an anti-myc tag antibody) and actin. (C) Thermal inactivation of the E1 ubiquitin-activating
enzyme prevented the loss of IRF-3 protein in the presence of Npro. ts20-derived cell populations with stable expression of control vector (Pur), L8P mutant Npro
(L8P), or WT NADL Npro (Npro) were either cultured at 35 °C or 39 °C for 16 h prior to whole cellular extract preparation and immunoblot analysis of murine IRF-3,
Npro (using an anti-myc tag antibody). A nonspecific band detected by the anti-IRF-3 antibody was shown to indicate equal loading. Although its nature remains
unknown, a protein band (marked by “*”) was detected by the anti-myc antibody and only present in cells expressingWTor L8P Npro and cultured at 39 °C. (D) Npro-
25 cells that were repressed (+tet) or induced (−tet) for Npro expression were mock-treated, or treated with 50 nM epoxomicin, and where indicated, along with 40 μM
ZVAD, a pan-caspase inhibitor, to enhance cell viability. Cell lysates were prepared and subjected to immunoprecipitation with a rabbit anti-IRF-3 antibody. The
immunoprecipitates were extensively washed, followed by immunoblot analysis using an mAb anti-ubiquitin (middle-panel) and an mAb anti-IRF-3 (lower panel).
One tenth of the protein lysates (input) were subjected to immunoblot analysis of Npro (using an anti-myc tag antibody), IRF-3 and actin (upper panels). (E) MDBK
cells with stable expression of WT Npro (Npro, lanes 1, 2, 5 and 6) or L8P mutant Npro (L8P, lanes 3, 4, 7 and 8) were cultured in the presence (lanes 2, 4, 6 and 8) or
absence (lanes 1, 3, 5 and 7) of epoxomicin and ZVAD. Cell lysates were prepared and subjected to immunoblot analysis for ubiquitin, IRF-3, and Npro/L8P (with an
anti-myc tag mAb) (left panels, lanes 1 through 4), or processed for IRF-3 immunoprecipitation followed by immunoblot analysis for ubiquitin (upper right panel). The
blot was subsequently stripped and reprobed for IRF-3 (lower right panel).
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To characterize the mechanism by which Npro induces IRF-
3 polyubiquitination, we asked whether Npro physically
interacts with IRF-3. Co-immunoprecipitation experiments did
not demonstrate the NADL Npro to be associated with IRF-3 in
either the Npro-29 (Fig. 8A, lane 7) or Npro-25 (Fig. 8C, lane 6)
cells under normal culture conditions. These data are similar to
those reported recently by Hilton et al. (Hilton et al., 2006) with
the ncp-pe515 Npro. However, we observed that Nproreproducibly co-precipitated with IRF-3 when cells were treated
with either of two different proteasome inhibitors, MG115 or
epoxomicin, with or without concomitant ZVAD (Fig. 8A, lane
8 and Fig. 8C, lanes 5, 7, and 8). In agreement with these data,
we found that Npro interacts with IRF-3 in MDBK cells stably
expressing Npro. While difficult to detect under normal culture
conditions, this interaction was much more easily demonstrated
following inhibition of the proteasome (Fig. 8B, compare lanes
14 vs. 13). Interestingly, the L8P mutant Npro was also able to
interact with IRF-3 under similar conditions (Fig. 8B, lanes 15
Fig. 8. Npro, but not PIN1, interacts with IRF-3 in the presence of proteasome inhibition. (A) Npro-29 cells repressed (+tet) or induced (−tet) for Npro expression were
mock treated or treated with 50 nM of epoxomixin along with 40 μM ZVAD, similarly to Fig. 7D. Cell lysates were immunoprecipitated with a rabbit anti-IRF-3
antibody followed by immunoblot analysis with mAb anti-IRF-3 or anti-myc tag (Npro) (right panels). Immunoblot analysis of the input (left panels) was conducted
similarly as Figs. 7C. (B) MDBK cells stably expressing the control vector (BKpur, lanes 1, 2, 11 and 12), Npro (BKNpro, lanes 3, 4, 13 and 14), or the mutant L8P
Npro (BKL8P, lanes 5, 6, 15 and 16), and HeLa Npro-25 cells (lanes 7 through 10 and 17 through 20) with (−tet) and without (+tet) Npro expression were mock treated
or treated with epoxomicin plus ZVAD. Left panels show immunoblot analysis of input for IRF-3, Npro, and actin. Note that the rabbit anti-IRF-3 antibody had greater
affinity for human IRF-3 (lanes 7 through 10) than bovine IRF-3 (lanes 1 through 6). In right panels (lanes 11 through 20), cell lysates were subjected to
immunoprecipitation with a rabbit anti-IRF-3 antibody followed by immunoblot analysis for WTor L8P Npro (using an mAb anti-myc tag), or IRF-3. The rabbit anti-
IRF-3 antibody was used to probe the immunoprecipitates as the mAb anti-IRF-3 did not detect bovine IRF-3. The dark shadowing behind the bovine and human
IRF-3 bands is the Ig heavy chain. Note that the human IRF-3 bands in lanes 19 and 20 (HeLa Npro-25 cells repressed for Npro expression) developed on the blot due
to their higher abundance and therefore, show bands of empty space. (C) Npro-25 cells induced for Npro expression (−tet) were mock-treated, or treated with 2 μM
MG115, or 50 nM epoxomicin, and where indicated 40 μMZVAD. The IRF-3 immunoprecipitates were subjected to immunoblot analysis with mAb anti-IRF-3, rabbit
anti-PIN1, and mAb anti-myc tag (Npro) (right panels). Left panels show immunoblot analysis of input for IRF-3, PIN1, Npro, and actin.
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ubiquitination and degradation (Figs. 7E, C, 4A and B) is not
due to an inability to interact with IRF-3. In aggregate, these
data suggest that wild-type Npro, but not the L8P mutant, is
capable of recruiting an additional cellular protein, perhaps an
E3 ubiquitin ligase, that is essential for polyubiquitination of
IRF-3. Although PIN1 has been reported to be recruited to IRF-
3 and to be essential for proteasomal degradation of IRF-3
following dsRNA stimulation or SeV infection (Saitoh et al.,
2006), we found no evidence for an interaction of PIN1 with
IRF-3 under these conditions (Fig. 8C). These data, togetherwith that Npro down-regulates IRF-3 in the absence of virus
infection (Figs. 4 and 7C), suggest that Npro induces the poly-
ubiquitination and proteasomal degradation of IRF-3 via a
PIN1-independent mechanism.
Discussion
While the ability of cpBVDVs to induce IFN has been
controversial (Brackenbury et al., 2003; Peterhans et al., 2003;
Schweizer et al., 2006), we have shown here that infection with
at least one cp strain of BVDV, NADL, like ncpBVDVs, does
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consistent with two recent reports (Gil et al., 2006; Schweizer et
al., 2006). Moreover, we have demonstrated that BVDV NADL
infection abrogates the IFN response triggered by SeV, which is
known to activate the RIG-I signaling pathway that is essential
for initiation of IFN responses to flaviviruses (Kato et al., 2006;
Li et al., 2005a; Yoneyama et al., 2004). Thus, the absence of
an IFN response in NADL BVDV infected cells is due to the
ability of NADL BVDV to actively block the host response.
Although it remains to be investigated whether different
cpBVDV strains may differentially modulate IFN responses,
our data suggest that the disruption of IFN induction is not a
unique feature of ncp BVDVs, but is also shared by at least
some cpBVDV strains, e.g. the NADL strain as we have shown
in this study.
Several previous studies have suggested a role for BVDV
Npro as an IFN antagonist (Gil et al., 2006; Horscroft et al.,
2005), but have left unanswered many questions concerning the
underlying mechanisms. Our data indicate that Npro expressed
during infection with a cpBVDV NADL strain inhibits host
responses triggered through IRF-3, the central regulator in type
I IFN synthesis, but leaves NF-κB activation of gene expression
unaffected (Fig. 2). Npro accomplishes this by post-transcrip-
tional down-regulation of IRF-3 protein abundance, thereby
effectively inhibiting IRF-3 dependent antiviral gene expression
initiated through either the TLR3 or RIG-I pathogen pattern
recognition receptors, the two major IFN-inducing pathways
present in most parenchymal cells (Akira et al., 2006).
Importantly, we have demonstrated this upon transient, stable,
and inducible expression of Npro as an isolated protein in cells
of human, bovine, and murine origin, as well as in bovine
kidney cells infected with BVDV. Very recently, Hilton et al.
(Hilton et al., 2006) reported similar results, showing blockade
of IFN induction by Npro using primarily promoter-based
reporter assays and quantitation of IFN-β mRNA. We have
shown here that Npro also inhibits virus-induced expression of
multiple ISGs: ISG56, ISG15, MxA and IFN-β. Nonetheless,
both studies lead to the same conclusion, that Npro specifically
targets the IRF-3 arm in innate antiviral responses and is a key
contributor to the disruption of IFN responses by BVDV.
Interestingly, the Npro of CSFV, another closely related
pestivirus, has also shown to block virus-induced IFN responses
(Bauhofer et al., 2007; La Rocca et al., 2005; Ruggli et al.,
2005).
Using a reverse-genetics approach, Gil et al. (Gil et al., 2006)
concluded that the N-terminal domain of Npro is important for
its ability to block the IFN response in BVDV-infected cells, as
BVDV mutants carrying substitutions within the N-terminus of
Npro (L8P, E22L, and H49V) induced IFN in infected cell
cultures (Gil et al., 2006). Hilton et al. recently demonstrated
that both N-terminal and C-terminal domains of Npro are
important, as removal of 30 aa from the N-terminus or 88 aa
from the C-terminus of ncp pe515 Npro abolished its ability to
inhibit dsRNA activation of IFN-β promoter (Hilton et al.,
2006). Our data are in agreement with these other studies.
Furthermore, we show that deletion of as few as 24 aa from the
C-terminus of the NADL Npro molecule completely abrogatesits ability to inhibit the IFN response (Fig. 3D and E). Con-
sistent with the observation by Gil et al. (Gil et al., 2006) that
BVDV carrying an L8P mutation in Npro induces IFN in cell
culture, we found that this catalytically-active Npro mutant is no
longer able to inhibit the induction of IFN by SeV infection
(Fig. 3C) or poly(I-C) (data not shown). Taken collectively,
these data show that the nearly full-length sequence of Npro is
essential to its function in antagonizing the IFN response, while
retention of Npro protease activity is not (Fig. 3). Further
studies are needed to determine the mechanisms by which these
mutations or deletions ablate the disruption of IFN signaling by
Npro, e.g., whether they do so by altering the folding/conforma-
tion of Npro or otherwise preventing its interactions with
cellular protein(s) involved in the down-regulation of IRF-3,
including perhaps IRF-3 itself.
We found that the cpNADL Npro down-regulates IRF-3
post-transcriptionally by inducing its polyubiquitination and
subsequent proteasome-dependent degradation, either in bovine
kidney MDBK cells infected with the NADL strain or
constitutively expressing NADL Npro, and in HeLa cells with
conditional expression of NADL Npro. These results are similar
to those reported recently by Hilton et al. (Hilton et al., 2006),
who demonstrated ubiquitination and proteasome-mediated
degradation of IRF-3 in calf testis cells infected with a
ncpBVDV strain (pe515) and in human HEp2 cells constitu-
tively expressing ncp pe515 Npro. Thus, the ability of Npro to
target IRF-3 for degradation is shared by both ncp and
cpBVDVs and is not host species specific, as it occurs in both
bovine and human cells. We have demonstrated in this study
that Npro-dependent, proteasome-mediated degradation of IRF-
3 requires prior polyubiquitination of IRF-3, as this occurred
only at temperatures permissive for E1 ubiquitin-activating
enzyme activity in murine fibroblast ts20 cells that express a
temperature-sensitive E1 mutant (Fig. 7C). This is important, as
not all proteins degraded by the proteasome undergo prior
polyubiquitination (Liu et al., 2005). Our data suggest that the
main effect of Npro may be to direct the polyubiquitination of
IRF-3, as we did not observe an accumulation of heterogenous
high molecular mass IRF-3–ubiquitin complexes in epoxomicin
and ZVAD-treated cells in the absence of Npro expression (Fig.
7D), nor did we see IRF-3 polyubiquitination in cells expressing
the L8P mutant Npro that is incapable of downregulating IRF-3
(Fig. 7E). Our data also indicate that virus-induced phosphor-
ylation of IRF-3 is not required for Npro-dependent IRF-3
ubiquitination, as this occurred in the absence of virus infection
in HeLa cells that conditionally expressed Npro under control of
a tet-regulated promoter (Fig. 7D) and in MDBK cells with
constitutive expression of Npro (Fig. 7E).
The precise mechanisms by which Npro induces the
polyubiquitination of IRF-3 and subsequently delivers it to
proteasomes remain unknown and await further careful
investigation. Previous studies have shown that a number of
viruses encode proteins that hijack the degradation machinery
of the proteasome to degrade cellular proteins (Chen and
Gerlier, 2006). This usually involves the association of cellular
targets with their viral partners, recruiting specific E3 ubiquitin
ligases to the complex to catalyze polyubiquitination of the
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papilloma virus E6 protein and cellular HECT domain E3
ligase, E6AP (Huibregtse et al., 1993). We were able to
demonstrate a weak interaction between Npro and IRF-3, which
was significantly enhanced when the 26S proteasome was
inhibited by treatment with MG115 or epoxomicin (Fig. 8). It is
possible that the interaction of IRF-3 with Npro quickly leads to
its polyubiquitination and subsequent destruction via the
proteasome, rendering it difficult to detect the Npro-IRF-3
complex. However, the L8P mutant Npro was also capable of
interacting with IRF-3, an association that was also enhanced by
proteasome inhibition (Fig. 8B). These results suggest that the
interaction between IRF-3 and Npro/L8P may be stabilized by
an unknown protein partner that is regulated by the proteasome.
While this requires further investigation, our data indicate that
the ability to interact with IRF-3 is not the sole determinant for
polyubiquitination of IRF-3 by Npro. Additional cellular
protein partner(s), including possibly an E3 ubiquitin ligase
(s), may need to be recruited to the Npro-IRF-3 complex, and
may interact efficiently with Npro but not the L8P mutant Npro.
Furthermore, our data indicate that IRF-3 ubiquitination may
not be a prerequisite for its interaction with Npro, as the L8P
mutant, which is incapable of inducing IRF-3 ubiquitination
(Fig. 7E), can also interact with IRF-3 (Fig. 8B). However, it is
important to keep in mind the possibility that a low level of IRF-
3 ubiquitination, below the limits of detection in our assay, may
be needed for its recognition by Npro.
While we have shown that the Npro-dependent polyubiqui-
tination of IRF-3 requires the E1 ubiquitin-activating enzyme
(Fig. 7C), the responsible E3 ligase remains to be identified.
Current understanding of the manner in which IRF-3 abundance
is regulated by the proteasome is limited. SeV infection triggers
C-terminal phosphorylation of IRF-3, which is followed by its
proteasome-dependent degradation (Lin et al., 1998). However,
these events may differ in different cell types (Foy et al., 2003).
Some evidence suggests that a cullin1-based ubiquitin ligase is
involved in the regulation of IRF-3 in SeV infected cells
following its C-terminal phosphorylation by TBK1 (Bibeau-
Poirier et al., 2006). However, other data suggest that the
peptidyl-prolyl isomerase PIN1 is recruited to phosphorylated
IRF-3 and essential for proteasome-dependent degradation of
IRF-3 following viral infections or TLR3 engagement (Saitoh et
al., 2006). Phosphorylation of IRF-3, especially at its Ser339
residue, appears to be a prerequisite for IRF-3 to be recognized
by PIN1. However, PIN1 does not directly catalyze ubiquitina-
tion or subsequent proteasome-dependent degradation of its
substrates, and its exact role in this process awaits further
investigation. However, preliminary data argue against the
involvement of PIN1 in Npro-mediated polyubiquitination of
IRF-3. Firstly, PIN1 was not recruited to the IRF-3–Npro
complex, regardless of the status of proteasome inhibition (Fig.
8C). Secondly, as mentioned above, Npro induced IRF-3
degradation in the absence of virus infection or dsRNA stimuli,
when IRF-3 was not phosphorylated (Figs. 4A, B and 7C).
Furthermore, although infection of MDBK cells with the
cpBVDV strain NADL induced IRF-3 degradation, this was not
the case with SeV infection (Figs. 1B and 4B). This suggeststhat BVDVand SeVare likely to utilize different mechanisms to
target IRF-3 for degradation.
The ability of the HCV NS3/4A protease to disrupt IRF-3-
dependent antiviral responses has been postulated to contribute
to HCV persistence (Foy et al., 2003). Classified with in the
same family Flaviviridae, both HCV and BVDV are able to
cause persistent infections in their respective hosts. However,
unlike HCV that frequently persists in adult humans, BVDV
persistence is only established following infection of develop-
ing fetuses with ncp viruses (Brock, 2003; Peterhans et al.,
2003). The fact that both cpBVDVand ncpBVDV share similar
mechanisms for ablating the expression of IRF-3 indicates that
the disruption of IRF-3-dependent host defenses is not by itself
sufficient for BVDV persistence. Nonetheless, such a mechan-
ism could contribute to the increased frequency and severity of
secondary infections in BVDV-infected animals (Fulton et al.,
2000; Peterhans et al., 2003; Potgieter, 1997). Although it is not
essential for either BVDVor CSFV replication (Lai et al., 2000;
Tratschin et al., 1998), Npro has been retained during the
evolution of all pestiviruses. It is also well conserved among
BVDV, CSFV, and BDV, sharing about 69% amino acid
sequence homology. Interestingly, the Npro of CSFV was also
shown very recently to target IRF-3 for proteasomal degrada-
tion (Bauhofer et al., 2007). Taken together, these facts suggest
that Npro-mediated interference with IRF-3-dependent host
defenses may play an important role in pestivirus pathogenesis.
It remains to be demonstrated whether variations in the
sequence of Npro contribute to altered pestivirus virulence in
vivo, and whether the latter can be related to the ability of
various Npros to interact with IRF-3 and/or other cellular
protein partners required for targeting IRF-3 for polyubiquitina-
tion and proteasome-mediated destruction.
Materials and methods
Cells and reagents
Human embryo kidney (HEK) 293, 293T, 293 cells stably
expressing human TLR3 (293-TLR3, kindly provided by Kate
Fitzgerald, University of Massachusetts), BOSC23 (kindly
provided by Shinji Makino, University of Texas Medical
Branch), HEC1B, and TH1 cells (Chen et al., 2007) (kindly
provided by Robert Lanford, Southwest Foundation for
Biomedical Research) were cultured by conventional techni-
ques. MDBK cells (kindly provided by Ilya Frolov, University
of Texas Medical Branch) were cultured similarly except that
horse serum was used in place of fetal bovine serum. HeLa Tet-
Off cells were maintained as indicated by the provider
(Clontech). BALB/c 3T3-derived ts20 cells expressing a
temperature-sensitive E1 ubiquitin-activating enzyme (Chowd-
ary et al., 1994) were kindly provided by Harvey L. Ozer
(UMDNJ-New Jersey Medical School) and cultured in DMEM
supplemented with 10% FBS, 100 μg/ml penicillin, and 100 μg/
ml streptomycin at 35 °C. Where indicated, cells were shifted to
the restricted temperature (39 °C) for 16 h to inactivate the
thermoliable E1. Stocks of cpBVDV NADL strain were kindly
provided by Ilya Frolov, University of Texas Medical Branch,
289Z. Chen et al. / Virology 366 (2007) 277–292and had a titer of ∼2×107 PFU/ml. The proteasome inhibitors,
MG-115 and epoxomicin, were purchased from Sigma and
Calbiochem, respectively. The pan-caspase inhibitor ZVAD-
FMK was from R&D Systems.
Plasmids
Plasmids were generated by conventional PCR techniques.
To construct a BVDV Npro expression vector, pcDNA6-Npro,
cDNA encoding NADL strain Npro (which represents the first
168 aa of the NADL polyprotein) was amplified by PCR from a
plasmid containing a copy of the BVDV NADL genome (kindly
provided by Ilya Frolov, University of Texas Medical Branch)
and subsequently ligated into pcDNA6/V5-HisB (Invitrogen).
To facilitate detection, we also constructed pcDNA6-mycNpro
and pcDNA6-Npro-V5, in which the Npro fragment was placed
in frame with an N-terminal c-myc tag or a C-terminal V5 tag,
respectively. To generate the Npro-CAT fusion construct, cDNA
encoding the chloramphenicol acetyltransferase (CAT) reporter
gene was fused to the C-terminus of Npro cDNA and cloned
into pBluescript. The junction between Npro and CAT contains
a consensus Npro cis-cleavage site and 6 amino acid residues of
BVDV capsid coding sequence, i.e., CPLWVTSC↓SDTKEE
(Npro cleavage recognition sequence in bold face letters)
(Rumenapf et al., 1998). The cDNA fragment encoding Npro-
CAT was subsequently swapped into pcDNA6-mycNpro to
generate pcDNA6-mycNpro-CAT. L8P, E22V, H49L, and
C69A mutants of Npro or Npro-CAT were generated by
QuikChange site-directed mutagenesis (Stratagene) in the
pcDNA6mycNpro and pcDNA6-mycNpro-CAT background,
respectively. The Npro deletion mutants, N69, C99, N99, N130,
and N144, were similarly generated in the pcDNA6-Npro-V5
background. To construct tet-regulated expression plasmids for
wild-type (WT) and L8P mutant Npro, cDNA fragments
encoding myc-tagged WT or L8P mutant Npro were cloned
into pTRE2Bla (Chen et al., 2007). To generate retroviral
expression constructs for WT and L8P mutant Npro, myc-Npro
and myc-NproL8P cDNA fragments were excised from
pTRE2Bla–mycNpro or pTRE2Bla–mycNproL8P, respec-
tively, and ligated with a replication-incompetent retroviral
expression vector, pCX4pur (a gift from Tsuyoshi Akagi, Osaka
Bioscience Institute) (Akagi et al., 2003).
Vectors expressing HCV NS3/4A, BVDV NS3/4A, human
TRIF, RIG-I, and MAVS/IPS-1/Cardif/VISA have been
described (Chen et al., 2007; Li et al., 2005a,b). pcDNA3–
FlagTBK1 and pcDNA3–FlagIKKε (Fitzgerald et al., 2003)
were kindly provided by Kate Fitzgerald (University of
Massachusetts). pEF-Bos(+), pEF-Bos RIG-I and pEF-Bos N-
RIG (Yoneyama et al., 2004) were gifts from Takashi Fujita
(Kyoto University). The reporter plasmids pIFN-β-Luc (Lin et
al., 1998), pISG56-Luc, PRDII-Luc(Fredericksen et al., 2002),
and (PRDIII-I)4-Luc (Ehrhardt et al., 2004) were kindly
provided by Rongtuan Lin (McGill University), Michael Gale
(University of Texas Southwestern Medical Center), and
Christina Ehrhardt (University of Wuerzburg), respectively.
pIRF3(-779)-Luc containing human IRF-3 promoter upstream
of firefly luciferase reporter gene was a gift from Paula Pitha-Rowe (Johns Hopkins University) (Lowther et al., 1999). The
pGL3-Control plasmid that contains the SV40 promoter
upstream of firefly luciferase gene was from Promega.
pCMVβgal (Clontech) or pRL-TK (Promega) were used to
normalize transfection efficiencies. Plasmid DNAs were
transfected into cells using Fugene 6 (Roche) or TransIT-LT1
(Mirus) (for HEK293 and TH1 cells), or Lipofectamine 2000
(Invitrogen, for HEC1B and HeLa cells), following the
manufacturer's instructions.
Establishment of HeLa cell lines with conditional expression of
BVDV Npro
HeLa Tet-Off cells (Clontech) were transfected with
pTRE2Bla-mycNpro or pTRE2Bla-mycNproL8P and double-
selected in complete medium supplemented with 100 μg/ml
G418, 1 μg/ml blasticidin and 2 μg/ml tetracycline. Three
weeks later, individual cell colonies were selected, expanded,
and examined for Npro expression by indirect immunofluores-
cence staining and immunoblot analysis with a monoclonal
antibody against c-myc tag (Cell Signaling Tech) after being
cultured in the absence of tet for 4 days. Cell clones that allowed
tight regulation of WT or L8P mutant Npro expression by
tetracycline were selected for further characterization. Two WT
Npro-inducible clones, designated Npro-25 and Npro-29, and
three L8P mutant cell lines, designated L8P-1, L8P-22 and L8P-
38, respectively, were used in this study.
Generation of MDBK and ts20 cells with stable expression of
Npro, L8P mutant Npro, or control vector
Replication-incompetent retroviruses encoding WT or L8P
mutant Npro, or the empty vector were harvested from
supernatants of BOSC23 cells cotransfected with pCL-10A1
(a gift from Tianyi Wang, University of Pittsburgh) and
pCX4pur-derived vectors encoding myc-tagged, WT or L8P
mutant Npro, or pCX4pur, respectively. The retroviruses were
subsequently used to transduce MDBK and ts20 cells in the
presence of 8 μg/ml of polybrene (Sigma). Following selection
with puromycin for ∼2 weeks, survived cell colonies were
pooled and used as a stable population for further analysis.
Poly (I-C) treatment and Sendai virus (SeV) infection
Where indicated, cells were incubated with 50 μg/ml of poly
(I-C) (Sigma) in culture medium for 8∼15 h, or infected with
100 hemagglutinin units (HAU)/ml of SeV (Cantell strain,
Charles River Laboratories) for 16 h prior to cell lysis for
luciferase/β-gal reporter assays and/or immunoprecipitation
/immunoblot analysis as previously described (Foy et al., 2003;
Li et al., 2005a,b).
Reporter gene assay
Cells (5×104 to 105 cells per well in 24 well plates) were
transfected with reporter plasmids (100 ng), pCMVβgal
(100 ng) and the indicated amount of an expression vector.
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poly (I-C), or challenged with SeV at 24 h posttranfection, and
subsequently lysed and assayed for luciferase and β-galactosi-
dase activities. For comparisons, luciferase activity was
normalized to β-galactosidase activity. In some experiments
renilla luciferase was used as an internal control and a dual-
luciferase assay was performed to calculate relative luciferase
activity. Data are expressed as mean relative luciferase activity
plus standard deviation for one representative experiment
carried out in triplicate, typically from a minimum of three
separate experiments. The fold-induction of promoter activity
was calculated by dividing the relative luciferase activity of
stimulated cells by that of mock-treated cells.
Indirect immunofluorescence staining
Cells grown in 4-well or 8-well chamber slides were fixed
and permeabilized, and subsequently immunostained with anti-
c-myc-tag antibody (Cell Signaling Tech, for detection of myc-
tagged Npro) and/or IRF-3 antisera (Navarro and David, 1999)
(a gift from Michael David, University of California, San
Diego) as previously described (Foy et al., 2003; Li et al.,
2002). Cells were examined under a Zeiss Axioplan II
fluorescence microscope or an LSM-510 META laser scanning
confocal microscope in the UTMB Optimal Imaging Core.
Immunoprecipitation and immunoblots
Cellular extracts were prepared, quantified, and subjected to
immunoprecipitation and/or immunoblot analysis as previous
described (Li et al., 2005a,b). The following monoclonal (mAb)
or polyclonal (pAb) antibodies were used: anti-c-myc tag mAb
and rabbit anti-PIN1 pAb (Cell Signaling Tech); anti-CAT pAb
and anti-FLAG M2 and anti-actin mAbs (Sigma); anti-V5 mAb
(Invitrogen); rabbit anti-BVDV NS3 pAb (a gift from Charles
Rice, Rockefeller University); rabbit anti-IRF-3 pAb (a gift
from Michael David, University of California-San Diego); anti-
CBP pAb and anti-IRF-3 and anti-ubiquitin mAbs (Santa Cruz);
rabbit anti-ISG56 pAb (a gift from Ganes Sen, Cleveland
Clinic); rabbit anti-ISG15 pAb (a gift from Arthur Haas,
Medical College of Wisconsin); rabbit anti-MxA and anti-
Sendai virus pAbs (gifts from Ilkka Julkunen, National Public
Health Institute, Helsinki); and peroxidase-conjugated second-
ary anti-rabbit and anti-mouse pAbs (Southern Biotech). Protein
bands were visualized using ECL Plus Western Blotting
detection reagents (GE HealthCare), followed by exposure to
X-ray film.
Northern blots
Total cellular RNA was isolated using RNeasy Mini Kit
(Qiagen) and subjected to Northern blot analysis by using
specific anti-sense riboprobes as per manufacturer's protocol
(NorthernMax Kit, Ambion). Briefly, 15–20 μg of total RNA
was fractionated on denaturing formaldehyde agarose (0.9%)
gels followed by capillary transfer to BrightStar-Plus Nylon
membrane (Ambion). Following UV cross-linking, membraneswere hybridized with 32P-labeled antisense riboprobes specific
to human ISG56, human IRF3, BVDV Npro, bovine IRF3 and
bovine ISG15 that were prepared by Maxiscript T7 kit
(Ambion) at 68 °C overnight. Subsequently, membranes were
extensively washed and autoradiographed or scanned with a
Phosphor-Imager (Molecular Dynamics). Ethidium bromide
staining of 28S and 18S rRNA was used as loading controls.
Quantitative real-time PCR
mRNAs for human IFN-β, IRF-3, and 18S rRNA were
quantified in total cellular RNA extracts using commercially
available primers and TaqMan probes (Applied Biosystems) by
RT-PCR at the UTMB Sealy Center for Cancer Biology Real
Time PCR Core. The relative abundance of each target was
obtained by normalization with endogenous 18S RNA.
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